ALX Oncology Holdings Inc ALXO
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-07-17 |
| Shares Out. | 134,560,000 |
| Website | alxoncology.com/ ↗ |
| Phone | 13026587581 |
| Employees | 48 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$18.0M |
| Free Cash Flow | -$71.0M |
| Total Assets | $160.8M |
| Total Liabilities | $24.6M |
| Equity | $136.2M |
About ALX Oncology Holdings Inc
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
ALX Oncology Holdings Inc is a publicly traded company under the ticker symbol ALXO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-09-01)